ArticleCurrent fungal infection reports2012
Progress Toward a Human Vaccine Against Coccidioidomycosis.
Article in Current fungal infection reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- A Review ofCurrent clinical microbiology reports · 2021Review
- CARD9-Associated Dectin-1 and Dectin-2 Are Required for Protective Immunity of a Multivalent Vaccine againstJournal of immunology (Baltimore, Md. : 1950) · 2020Article
- A review of innate and adaptive immunity to coccidioidomycosis.Medical mycology · 2019Review
- The Rise ofFrontiers in immunology · 2019Review
- Investigating the Relationship Between Climate and Valley Fever (Coccidioidomycosis).EcoHealth · 2018Article
- Glucan-Chitin Particles Enhance Th17 Response and Improve Protective Efficacy of a Multivalent Antigen (rCpa1) against Pulmonary Coccidioides posadasii Infection.Infection and immunity · 2018Article
- Immune Response to Coccidioidomycosis and the Development of a Vaccine.Microorganisms · 2017Review
- Coccidioidomycosis causing osteomyelitis of the hand in an immunocompetent patient.Hand (New York, N.Y.) · 2015Article
- Vaccine immunity against fungal infections.Current opinion in immunology · 2014Review
- Interleukin-1 receptor but not Toll-like receptor 2 is essential for MyD88-dependent Th17 immunity to Coccidioides infection.Infection and immunity · 2014Article
- Novel strategies to enhance vaccine immunity against coccidioidomycosis.PLoS pathogens · 2013Article
- Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis.Infection and immunity · 2012Article
- Extracellular ammonia at sites of pulmonary infection with Coccidioides posadasii contributes to severity of the respiratory disease.Microbial pathogenesisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Coccidioidomycosis (San Joaquin Valley fever) is a human respiratory disease caused by a soil-borne mold, and is recognized as an intransigent microbial infection by physicians who treat patients with the potentially life-threatening, disseminated form of this mycosis. Epidemiological studies based on surveys of skin-test reactivity of people who reside in the endemic regions of the Southwestern US have shown that at least 150,000 new infections occur annually. The clinical spectrum of coccidioidomycosis ranges from an asymptomatic insult to a severe pulmonary disease in which the pathogen may spread from the lungs to the skin, bones, brain and other body organs. Escalation of symptomatic infections and increased cost of long-term antifungal treatment warrant a concerted effort to develop a vaccine against coccidioidomycosis. This review examines recently reported strategies used to generate such a vaccine and summarizes current understanding of the nature of protective immunity to this formidable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.